Overview

A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

Status:
RECRUITING
Trial end date:
2025-12-21
Target enrollment:
Participant gender:
Summary
This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).
Phase:
PHASE2
Details
Lead Sponsor:
ResoTher Pharma